Semicarbazide-sensitive amine oxidase and kidney disease

American Journal of Physiology - Renal Physiology

Volumn 305, Issue 12, 2013, Pages

  Wong, May Y W ^a   Saad, Sonia ^a   Pollock, Carol ^a   Wong, Muh Geot ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Anti inflammatory; Chronic kidney disease; Semicarba zide sensitive amine oxidase; Tubulointerstitial fibrosis

Indexed keywords

ACROLEIN; ADRENALIN; ADVANCED GLYCATION END PRODUCT; ALDEHYDE; ALLYLAMINE; AMINE OXIDASE (COPPER CONTAINING); AMINE OXIDASE (FLAVIN CONTAINING); AMINO ACID; ANGIOTENSIN; BENZYLAMINE; CELL ADHESION MOLECULE; COLLAGEN FIBER; CREATININE; CYTOKINE; DOPAMINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENZYME; GLUCOSE TRANSPORTER; HISTAMINE; INSULIN; MATRIX PROTEIN; METHYLAMINE; OXYGEN RADICAL; PADGEM PROTEIN; PHENETHYLAMINE; SELEGILINE; TRYPTAMINE; TYRAMINE; UNINDEXED DRUG; VASCULAR ADHESION PROTEIN 1;

ADIPOCYTE; AEROBIC METABOLISM; ARTERIOSCLEROSIS; ATROPHY; BRAIN INFARCTION; CELL DIFFERENTIATION; CELL MIGRATION; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; DEAMINATION; DIABETES MELLITUS; ENZYME SPECIFICITY; EXTRACELLULAR MATRIX; FIBROSING ALVEOLITIS; GLOMERULOSCLEROSIS; GLUCOSE TRANSPORT; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFLAMMATION; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY FIBROSIS; LIVER DISEASE; LYMPHOCYTE; MALIGNANT HYPERTENSION; MOLECULAR MODEL; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASCULAR SMOOTH MUSCLE;

ANTI-INFLAMMATORY; CHRONIC KIDNEY DISEASE; SEMICARBAZIDE-SENSITIVE AMINE OXIDASE; TUBULOINTERSTITIAL FIBROSIS;

AMINE OXIDASE (COPPER-CONTAINING); ENZYME INHIBITORS; HUMANS; KIDNEY; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 84890401313     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00416.2013     Document Type: Review

References (106)

1. Abella A, Garcia-Vicente S, Viguerie N, Ros-Baró A, Camps M, Palacín M, Zorzano A, Marti L. Adipocytes release a soluble form of VAP-1/SSAO by a metalloprotease-dependent process and in a regulated manner. Diabetologia 47: 429-438, 2004.
2. + monocytes across human liver sinusoidal endothelium. Hepatology 51: 2030-2039, 2010.
3. Baba S, Watanabe Y, Gejyo F, Arakwa M. High-performance liquid chromatographic determination of serum aliphatic amines in chronic renal failure. Clin Chim Acta 136: 49-56, 1984.
4. Barri Y. Hypertension and kidney disease: a deadly connection. Curr Cardiol Rep 8: 411-417, 2006.
5. Beisswenger PJMZ, Curphey TJ, Moore LL, Jean S, Brinck-Johnsen T, Bucala R, Vlassara H. Formation of immunochemical advanced glycosylationend products precedes and correlates with early-manifestations of renal and retinal disease in diabetes. Diabetes Care 44: 824-829, 1995.
6. BIOTIE Therapies. VAP-1 Antibody for Inflammatory/Fibrotic Disease (online). http://www.biotie.com/en/product_and_development/idevelopment_pipeline/vap1_antibody [4 November 2013].
7. Bohle A, Christ H, Grund K, Mackensen S. The role of the interstitium of the renal cortex in renal disease. Contrib Nephrol 16: 109-114, 1979.
8. Bohle A, Mackensen-Haen S, von Gise H. Significance of tubulointer-stitial changes in the renal cortex for the excretory function and concentration ability of the kidney: a morphometric contribution. Am J Nephrol 7: 421-433, 1987.
9. Bolt H. Experimental toxicology of formaldehyde. J Cancer Res Clin Oncol 13: 305-309, 1987.
10. Boomsma F, Bhaggoe U, van der Houwen A, van den Meiracker A. Plasma semicarbazide-sensitive amine oxidase in human (pathophysiology. Biochim Biophys Acta 1647: 48-54, 2003.
11. Boomsma F, Derkx F, van den Meiracker A, Man ińt Veld A, Schalekamp M. Plasma semicarbazide-sensitive amine oxidase activity is elevated in diabetes mellitus and correlates with glycosylated haemoglobin. Clin Sci (Lond) 88: 675-679, 1995.
12. Boomsma F, van den Meiracker A, Winkle S. Circulating semicarbazide-sensitive amine oxidase is raised both in type I (insulin-dependent), in type II (non-insulin-dependent) diabetes mellitus and even in childhood type I diabetes at first clinical diagnosis. Diabetologia 42: 233-237, 1999.
13. Boomsma F, van Veldhuisen D, de Kam P, Man ińt Veld A, Mosterd A, Lie K, Schalekamp M. Plasma semicarbazide-sensitive amine oxidase is elevated in patients with congestive heart failure. Cardiovasc Res 33: 387-391, 1997.
14. Boor PJ, Hysmith RM, Sanduja R. A role for a new vascular enzyme in the metabolism of xenobiotic amines. Circ Res 66: 249-252, 1990.
15. Chen K, Maley J, Yu P. Potential implications of endogenous aldehydes in fj-amyloid misfolding, oligomerization and fibrillogenesis. J Neuro-chem 99: 1413-1424, 2006.
16. ClinicalTrials.gov, National Institutes of Health. The Relationship Between Vascular Adhesion Protein-1 and Diabetic Cardiovascular Autonomic Neuropathy (online). http://www.clinicaltrials.gov/ct2/show/NCT01706289?term=vap1&rank=1 [4 November 2013].
17. Conklin D, Langford S, Boor P. Contribution of serum and cellular semicarbazide-sensitive amine oxidase to amine metabolism and cardiovascular toxicity. Toxicol Sci 46: 386-392, 1998.
18. Dunkel P, Balogh B, Meleddu R, Maccioni E, Gyires K, Mátyus P. Semicarbazide-sensitive amine oxidase/vascular adhesion protein-1: a patent survey. Expert Opin Ther Pat 21: 1453-1471, 2011.
19. Dunkel P, Gelain A, Barlocco D, Haider N, Gyires K, Sperlálagh B, Magyar K, Maccioni E, Fadda A, Mátyus P. Semicarbazide-sensitive amine oxidase/vascular adhesion protein 1: recent developments concerning substrates and inhibitors of a promising therapeutic target. Curr Med Chem 15: 1827-1839, 2008.
20. Ekblom J. Potential therapeutic value of drugs inhibiting semicarbazide-sensitive amine oxidase: vascular cytoprotection in diabetes mellitus. Pharmacol Res 37: 87-92, 1998.
21. El Hadri K, Moldes M, Mercier N, Andreani M, Pairault J, Feve B. Semicarbazide-sensitive amine oxidase in vascular smooth muscle cells: differentiation-dependent expression and role in glucose uptake. Arterio-scler Thromb Vasc Biol 22: 89-94, 2002.
22. Elliott J, Fowden A, Callingham B, Sharman D, Silver M. Physiological and pathological influences on sheep blood plasma amine oxi-dase: effect of pregnancy and experimental alloxan-induced diabetes mellitus. Res Vet Sci 50: 334-339, 1991.
23. Enrique-Tarancón G, Martí L, Morin N, Lizcano J, Unzeta M, Sevilla L, Camps C, Palacín M, Testar X, Carpené C, Zorzano A. Role of semicarbazide-sensitive amine oxidase on glucose transport GLUT4 recruitment to the cell surface in adipose cells. J Biol Chem 273: 8025-8032, 1998.
24. Eremina V, Baelde H, Quaggin S. Role of the VEGF-A signaling pathway in the glomerulus: evidence for crosstalk between components of the glomerular filtration barrier. Nephron Physiol 106: 32-37, 2007.
25. Freedman B, Wuerth J, Cartwright K, Bain R, Dippe S, Hershon K, Mooradian A, Spinowitz B. Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control Clin Trials 20: 493-510, 1999.
26. Garpenstrand H, Ekblom J, Backlund L, Oreland L, Rosenqvist U. Increased plasma semicarbazide-sensitive amine oxidase (SSAO) activity in type 2 diabetes mellitus complicated by retinopathy. Diabet Med 16: 514-521, 1999.
27. Gokturk C, Nilsson J, Nordquist J, Kristensson M, Svensson K, Soderberg C, Israelson M, Garpenstrand H, Sjoquist M, Oreland L, Forsberg-Nilsson K. Overexpression of semicarbazide-sensitive amine oxidase in smooth muscle cells leads to an abnormal structure of the aortic elastic laminas. Am J Pathol 163: 1921-1928, 2003.
28. Gubisne-Haberle D, Hill W, Kazachkov M, Richardson J, Yu P. Protein cross-linkage induced by formaldehyde derived from semicarba-zide-sensitive amine oxidase-mediated deamination of methylamine. J Pharmacol Exp Ther 310: 1125-1132, 2004.
29. Hayes B, Clarke D. Semicarbazide-sensitive amine oxidase activity in streptozotocin diabetic rats. Res Commun Chem Pathol Pharmacol 69: 71-83, 1990.
30. Heck H, Casanova M, Starr T. Formaldehyde toxicity-new understanding. Crit Rev Toxicol 20: 397-426, 1990.
31. Holmen C, Elsheikh E, Christensson M, Liu J, Johansson A, Qureshi A, Jalkanen S, Sumitran-Holgersson S. Anti-endothelial cell autoanti-bodies selectively activate SAPK/JNK signalling in Wegener's granulo-matosis. J Am Soc Nephrol 18: 2497-2508, 2007.
32. Holt A, Alton G, Scaman CH, Loppnow GR, Szpacenko A, Svendsen I, Palcic MM. Identification of the quinone cofactor in mammalian semicarbazide- sensitive amine oxidase. Biochemistry 37: 4946-4957, 1998.
33. Hooper N, Karran E, Turner A. Membrane protein secretases. Biochem J 321: 265-279, 1997.
34. Ienaga K, Nakamura K, Hochi T, Nakazawa Y, Fukunaga Y, Kakita H, Nakano K. Crosslines, fluorophores in the AGE-related cross-linked proteins. Contrib Nephrol 112: 42-51, 1995.
35. Ishizaki F. Plasma benzylamine oxidase activity in cerebrovascular disease. Eur Neurol 30: 104-107, 1990.
36. Jaakkola K, Nikula T, Holopainen R, Vahasilta T, Matikainen M, Laukkanen M, Huupponen R, Halkola L, Nieminen L, Hiltunen J. In vivo detection of vascular adhesion protein-1 in experimental inflammation. Am J Pathol 157: 463-471, 2000.
37. Jalkanen S, Salmi M. VAP-1 and CD73, endothelial cell surface enzymes in leukocyte extravasation. Arterioscler Thromb Vasc Biol 28: 18-26, 2008.
38. Kirton C, Laukkanen M, Nieminen A, Merinen M, Stolen C, Armour K, Smith D, Salmi M, Jalkanen S, Clark M. Function-blocking antibodies to human vascular adhesion protein-1: a potential anti-in-flamatory therapy. Eur J Immunol 35: 3119-3313, 2005.
39. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Stam-ler J. End-stage renal disease in African-American and white men: 16-year MRFIT findings. JAMA 277: 1293-1298, 1997.
40. Koc-Zorawska E, Malyszko J, Malyszko J, Mysliwiec M. VAP-1, a novel molecule linked to endothelial damage and kidney function in kidney allograft recipients. Kidney Blood Press Res 36: 242-247, 2012.
41. Koskinen K, Nevalainen S, Karikoski M, Hänninen A, Jalkanen S, Salmi M. VAP-1-deficient mice display defects in mucosal immunity and antimicrobial responses: implications for antiadhesive applications. J Immunol 179: 6160-6168, 2007.
42. Kurkijarvi R, Adams D, Leino R, Mottonen T, Jalkanen S, Salmi M. Circulating form of human vascular adhesion protein-1 (VAP-1): increased serum levels in inflammatory liver diseases. J Immunol 161: 1549-1557, 1998.
43. Kurkijarvi R, Jalkanen S, Isoniemi H, Salmi M. Vascular adhesion protein-1 (VAP-1) mediates lymphocyte-endothelial interactions in chronic kidney rejection. Eur J Immunol 31: 2876-2884, 2001.
44. Lalor PF, Sun PJ, Weston CJ, Martin-Santos A, Wakelam MJ, Adams DH. Activation of vascular adhesion protein-1 on liver endothelium results in an NF-KB-dependent increase in lymphocyte adhesion. Hepatology 45: 465-474, 2007.
45. Langford S, Trent M, Boor P. Semicarbazide-sensitive amine oxidase and extracellular matrix deposition by smooth muscle cells. Cardiovasc Toxicol 2: 141-150, 2002.
46. Langford SD, Trent MB, Balakumaran A, Boor PJ. Developmental vasculotoxicity associated with inhibition of semicarbazide-sensitive amine oxidase. Toxicol Appl Pharmacol 155: 237-244, 1999.
47. Lewinsohn R. Mammalian monoamine-oxidizing enzymes with special reference to benzylamine oxidase in human tissues. Braz J Med Biol Res, 17: 223-56, 1984.
48. Lewinsohn R, Böhm K, Glover V, Sandler M. A benzylamine oxidase distinct from monoamine oxidase B-widespread distribution in man and rat. Biochem Pharmacol 27: 1857-1863, 1978.
49. Li H, Lin M, Wei J, Hung C, Chiang F, Lin C, Hsu H, Su C, Wu M, Smith D, Vainio J, Chen M, Chuang L. Change of serum vascular adhesion protein-1 after glucose loading correlates to carotid intima medial thickness in non-diabetic subjects. Clin Chim Acta 403: 97-101, 2009.
50. Li H, Wei J, Lin M, Smith D, Vainio J, Lin C, Chiang F, Shih S, Huang C, Wu M, Hsein Y, Chuang L. Serum vascular adhesion protein-1 is increased in acute and chronic hyperglycemia. Clin Chim Acta 404: 149-153, 2009.
51. Lin M, Li H, Wei J, Lin C, Smith D, Vainio J, Shih S, Chen Y, Lin L, Kao H, Chuang L, Chen M. Serum vascular adhesion protein-1 is higher in subjects with early stages of chronic kidney disease. Clin Biochem 41: 1362-1367, 2008.
52. Lo T, Westwood M, McLellan A, Selwood T, Thornalley P. Binding and modification of proteins by methylglyoxal under physiological conditions. J Biol Chem 269: 32299-32305, 1994.
53. Lyles GA, Chalmers J. Aminoacetone metabolism by semicarbazide-sensitive amine oxidase in rat aorta. Biochem Pharmacol 49: 416-419, 1995.
54. Lyles GA, Singh I. Vascular smooth muscle cells: a major source of the semicarbazide-sensitive amine oxidase of the rat aorta. J Pharm Pharmacol 37: 637-643, 1985.
55. Makita Z, Radoff S, Rayfield E, Yang Z, Skolnik E, Delaney V, Friedman E, Cerami A, Vlassara H. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 325: 836-842, 1991.
56. Marti L, Morin N, Enrique-Tarancon G, Prevot D, Lafontan M, Testar X, Zorzano A, Carpene C. Tyramine and vanadate synergisti-cally stimulate glucose transport in rat adipocytes by amine oxidase-dependent generation of hydrogen peroxide. J Pharmacol Exp Ther 285: 342-349, 1998.
57. Marttila-Ichihara F, Smith DJ, Stolen C, Yegutkin GG, Elima K, Mercier N, Kiviranta R, Pihlavisto M, Alaranta S, Pentikäinen U, Pentikäinen O, Fülöp F, Jalkanen S, Salmi M. Vascular amine oxidases are needed for leukocyte extravasation into inflamed joints in vivo. Arthritis Rheum 54: 2852-2862, 2006.
58. Mátyus P, Dajka-Halász B, Földi A, Haider N, Barlocco D, Magyar K. Semicarbazide-sensitive amine oxidase: current status and perspectives. Curr Med Chem 11: 1285-1298, 2004.
59. McDonald I, Foot J, Yin P, Flening E, van Dam E. Semicarbazide sensitive amine oxidase and vascular adhesion protein-1: one protein being validated as a therapeutic target for inflammatory diseases. Ann Rep Med Chem 42: 229-243, 2007.
60. McEwen CM, Cohen JD. An amine oxidase in normal human serum. J Lab Clin Med 62: 766-776, 1963.
61. McGinn S, Poronnik P, Gallery E, Pollock C. A method for the isolation of glomerular and tubulointerstitial endothelial cells and a comparison of characteristics with the human umbilical vein endothelial cell model. Nephrology (Carlton) 9: 229-237, 2004.
62. McLellan A, Phillips S, Thornalley P. The assay of methylglyoxal in biological systems by derivatization with diamno-4,5-dimethoxyben-zene. Anal Biochem 206: 17-23, 1992.
63. McLellan M, Thornalley P, Benn J, Sonksen P. Glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications. Clin Sci Colch 87: 21-29, 1994.
64. Mercier N, Moldes M, El Hadri K, Feve B. Semicarbazide-sensitive amine oxidase activation promotes adipose conversion of 3T3-L1 cells. Biochem J 358: 335-342, 2001.
65. Mercier N, Osborne-Pellegrin M, El Hadri K, Kakou A, Labat C, Loufrani L, Henrion D, Challande P, Jalkanen S, Fève B, Lacolley P. Carotid arterial stiffness, elastic fibre network and vasoreactivity in semicarbazide-sensitive amine-oxidase null mouse. Cardiovasc Res 72: 349-357, 2006.
66. Meszaros Z, Szombathy T, Raimondi L, Karadi I, Romics L, Magyar K. Increased serum semicarbazide-sensitive amine oxidase activity in non-insulin-dependent diabetes mellitus: correlation with body mass index and serum triglyceride. Metabolism 48: 113-117, 1999.
67. Monnier V, Sell DR, Nagaraj RH, Miyata S, Grandhee S, Odetti P, Ibrahim SA. Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia. Diabetes Care 41: 36-41, 1992.
68. Morin N, Lizcano JM, Fontana E, Marti L, Smih F, Rouet P, Prévot D, Zorzano A, Unzeta M, Carpéné C. Semicarbazide-sensitive amine oxidase substrate stimulate glucose transport and inhibits lypolysis in human adipocytes. J Pharmacol Exp Ther 297: 563-572, 2001.
69. Morris N, Ducret A, Aebersold R, Ross S, Keller S, Lienhard G. Membrane amine oxidase cloning and identification as a major protein in the adipocyte plasma membrane. J Biol Chem 272: 9388-9392, 1997.
70. Nagaraj R, Shipanova I, Faust F. Protein cross-linking by the Mailard reaction. Isolation, characterization and in vivo detection of a lysine-lysine cross-link derived from methylglyoxal. J Biol Chem 271: 19338-19345, 1996.
71. Nath K. The tubulointerstitium in progressive renal disease. Kidney Int 54: 992-994, 1998.
72. Nelson TJ, Boor PJ. Allylamine cardiotoxicity-IV. Metabolism to acrolein by cardiovascular tissues. Biochem Pharmacol 31: 509-514, 1982.
73. Nemcsik J, Szökö E, Soltész Z, Fodor E, Toth L, Egresits J, Tábi T, Magyar K, Kiss I. Alteration of serum semicarbazide-sensitive amine oxidase activity in chronic renal failure. J Neural Transm 114: 841-843, 2007.
74. Nilsson S, Tryding N, Tufvesson G. Serum monoamine oxidase in diabetes mellitus and some other internal diseases. Acta Med Scand 184: 105-108, 1968.
75. Noda K, She H, Nakazawa T, Hisatomi T, Nakao S, Almulki L, Zandi S, Miyahara S, Ito Y, Thomas KL, Garland RC, Miller JW, Gra-goudas ES, Mashima Y, Hafezi-Moghadam A. Vascular adhesion protein-1 blockade suppresses choroidal neovascularization. FASEB J 22: 2928-2935, 2008.
76. O'Sullivan J, Unzeta M, Healy J, O'Sullivan M, Davey G, Tipton K. Semicarbazide-sensitive amine oxidases: enzymes with quite a lot to do. Neurotoxicology 25: 303-315, 2004.
77. O'Rourke A, Wang E, Miller A, Podar E, Scheyhing K, Huang L, Kessler C, Gao H, Ton-Nu H, MacDonald M, Jones D, Linnik M. Anti-inflammatory effects of LJP 1586 [Z-3-fluoro-2-(4- methoxybenzyl) allylamine hydrochloride], an amine-based inhibitor of semicarbazide-sensitive amine oxidase activity. J Pharmacol Exp Ther 324: 867-875, 2008.
78. Precious E, Lyles GA. Properties of a semicarbazide-sensitive amine oxidase in human umbilical artery. J Pharm Pharmacol 40: 627-633, 1988.
79. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 116: 288-296, 2006.
80. Sagrinati C, Netti G, Mazzinghi B, Lazzeri E, Liotta F, Frosali F, Ronconi E, Meini C, Gacci M, Squecco R, Carini M, Gesualdo L, Francini F, Maggi E, Annunziato F, Lasagni L, Serio M, Romagnani S, Romagnani P. Isolation and characterization of multipotent progenitor cells from the Bowman's capsule of adult human kidneys. J Am Soc Nephrol 17: 2443-2456, 2006.
81. Salmi M, Jalkanen S. Developmental regulation of the adhesive and enzymatic activity of vascular adhesion protein-1 (VAP-1) in humans. Blood 108: 1555-1561, 2006.
82. Salmi M, Kalimo K, Jalkanen S. Induction and function of vascular adhesion protein-1 at sites of inflammation. J Exp Med 178: 2255-2260, 1993.
83. Salmi M, Stolen C, Jousilahti P, Yegutkin G, Tapanainen P, Jana-tuinen T, Knip M, Jalkanen S, Salomaa V. Insulin-regulated increase of soluble vascular adhesion protein-1 in diabetes. Am J Pathol 161: 2255-2262, 2002.
84. Salmi M, Yegutkin G, Lehvonen R, Koskinen K, Salminen T, Jal-kanen S. A cell surface amine oxidase directly controls lymphocyte migration. Immunity 14: 265-276, 2001.
85. Salmi M, Yegutkin GG, Lehvonen R, Koskinen K, Salminen T, Jalkanen S. A cell surface amine oxidase directly controls lymphocyte migration. Immunity 14: 265-276, 2001.
86. Salter-Cid LM, Wang E, O'Rourke AM, Miller A, Gao H, Huang L, Garcia A, Linnik MD. Anti-inflammatory effects of inhibiting the amine oxidase activity of semicarbazide-sensitive amine oxidase. J Pharmacol Exp Ther 315: 553-562, 2005.
87. Schröder S, Palinski W, Schmid-Schönbein G. Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. Am J Pathol 139: 81-100, 1991.
88. Smith D, Salmi M, Bono P, Hellman J, Leu T, Jalkanen S. Cloning of vascular adhesion protein 1 reveals a novel multifunctional adhesion molecule. J Exp Med 188: 17-27, 1998.
89. Souto R, Vallega G, Wharton J, Vinten J, Tranum-Jensen J, Pilch P. Immunopurification and characterization of rat adipocyte caveolae suggest their dissociation from insulin signaling. J Biol Chem 278: 18321-18329, 2003.
90. Stolen C, Madanat R, Marti L, Kari S, Yegutkin G, Sariola H, Zorzano A, Jalkanen S. Semicarbazide sensitive amine oxidase over-expression has dual consequences: insulin mimicry and diabetes-like complications. FASEB J 18: 702-704, 2004.
91. Stolen C, Martilla-Ichihara F, Koskinen K, Yegutkin G, Turja R, Bono P, Skurnik M, Hanninen A, Jalkanen S, Salmi M. Absence of the endothelial oxidase AOC3 leads to abnormal leukocyte traffic in vivo. Immunity 22: 105-115, 2005.
92. Thornalley P. Methylglyoxal, glyoxalases and the development of diabetic complications. Amino Acids 6: 15-23, 1994.
93. Tryding N, Nilsson S, Tufvesson G. Physiological and pathological influences on serum monoamine oxidase level. Scand J Clin Lab Invest 23: 79-84, 1969.
94. Vainio P, Kortekangas-Savolainen O, Mikkola J, Jaakkola K, Kalimo K, Jalkanen S, Veromaa T. Safety of blocking vascular adhesion protein-1 in patients with contact dermatitis. Basic Clin Pharmacol Toxicol 96: 429-435, 2005.
95. Vidrio H, Medina M, González-Romo P, Lorenzana-Jiménez M, Diaz-Arista P, Baeza A. Semicarbazide-sensitive amine oxidase substrates potentiate hydralazine hypotension: possible role of hydrogen peroxide. J Pharmacol Exp Ther 307: 497-504, 2003.
96. Vilayur E, Harris D. Emerging therapies for chronic kidney disease: what is their role? Nat Rev Nephrol 5: 375-383, 2009.
97. Yu C, Wang F, Jin C, Wu X, Chan W, McKeehan W. Increased carbon tetrachloride-induced liver Injury and fibrosis in FGFR4-deficient mice. Am J Pathol 161: 2003-2010, 2002.
98. Yu P. Semicarbazide-sensitive amine oxidase and mortality in chronic heart failure. Eur Heart J 21: 1812-1814, 2000.
99. Yu P, Deng Y. Potential cytotoxic effect of chronic administration of creatine, a nutrition supplement to augment athletic performance. Med Hypotheses 54: 726-728, 1999.
100. Yu P, Dyck R. Impairment of methylamine clearance in uremic patients and its nephropathological implications. Clin Nephrol 49: 299-302, 1998.
101. Yu P, Lai C, Zuo D. Formation of formaldehyde from adrenaline in vivo; a potential risk factor for stress-related angiopathy. Neurochem Res 22: 615-620, 1997.
102. Yu P, Wright S, Fan E, Lun Z, Gubisne-Harberle D. Physiological and pathological implications of semicarbazide-sensitive amine oxidase. Biochim Biophys Acta 1647: 193-199, 2003.
103. Yu P, Zuo D. Methylamine, a potential endogenous toxin for vascular tissues: formation of formaldehyde via enzymatic deamination and the cytotoxic effects on endothelial cells. Diabetes Care 42: 594-603, 1993.
104. Yu P, Zuo D. Formaldehyde produced endogenously via deamination of methylamine. A potential risk factor for initiation of endothelial injury. Atherosclerosis 120: 189-197, 1996.
105. Yu P, Zuo D. Aminoguanidine inhibits semicarbazide-sensitive amine oxidase activity: implications for advanced glycation and diabetic complications. Diabetologia 40: 1243-1250, 1997.
106. Zorzano A, Abella A, Marti L, Carpéné C, Palacin M, Testar X. Semicarbazide-sensitive amine oxidase activity exerts insulin-like effects on glucose metabolism and insulin-signaling pathways in adipose cells. Biochim Biophys Acta 1647: 3-9, 2003.